Limited Competition
Because Fabry disease is such a difficult-to-treat condition, there aren’t many therapeituc options out there. As such, if PLX were to break into this market, it would have little competition to contend with.
While the company wouldn’t need to take a large percentage of the market to create meaningful growth for investors, the potential of this happening is there.
Think about it this way. In the Phase 3 clinical trial, the drug is showing to be as effective as, if not more effective than, the current standard of care.
If you had Fabry disease or were a doctor treating patients with the condition, chances are that you’d like to use the best therapeutic option out there. With limited competition and strong data, PLX may just be sitting on this option!
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!